Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 5/14/2017
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||- / 2||UN / IM|
Administered by: Other Purchased by: Other
Symptoms: Abdominal pain, Arthralgia, Sleep disorder, Syncope, Weight decreased, Weight increased, Orthostatic intolerance, Tilt table test positive
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? No
Other Medications: No other medications
Current Illness: Human papilloma virus immunisation
Diagnostic Lab Data: Test examinations: During tilt table test orthostatic intolerance, but do not fulfill the criteria for Postural Orthostatic Tachycardia Syndrome (POTS).
CDC 'Split Type': WAES1512DNK010833
Write-up:Information has been received from Sanofi Pasteur MSD (SPM) (manufacturer control # DK-1577272925-2015001177) on 21-DEC-2015. Case received from a physician via health authority on 17-Dec-2015 under reference number DK-DKMA-WBS-0002100. A 12-year-old female adolescent patient received GARDASIL, batch number unknown via intramuscular route in May-2012. The patient experienced Joint pain in JUL-2012, Weight - gaining and then loosing in JUL-2012, Syncope on an unknown date, Abdominal pain on an unknown date and Sleep disorder on an unknown date. The patient had received previously two doses of GARDASIL (not reported dates). Onset after third dose (May 2012) approx. 2 months after administration. She describes that she had developed joint pain and that her weight is unstable she gain and she loose. After the other reactions. She does not remember the dates of the first 2 doses. Additional investigations included Tilt Table Test orthostatic intolerance on an unknown date. The patient''s outcome was reported as Not Recovered/Not Resolved.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166